ID

23148

Beschreibung

Treatment of Non-Metastatic Hepatocellular Carcinoma in Humans by Increasing Gabaergic Activity: A Pilot Study; ODM derived from: https://clinicaltrials.gov/show/NCT00493428

Link

https://clinicaltrials.gov/show/NCT00493428

Stichworte

Versionen (1)
  1. 26.06.17 26.06.17 -
Hochgeladen am

26. Juni 2017

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY 4.0
Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Zurück zu Modell Kommentaren
Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Hepatocellular Carcinoma NCT00493428

Englisch

Eligibility Hepatocellular Carcinoma NCT00493428

1 Formulare  
Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
a diagnosis of hcc and no evidence of extra-hepatic metastases on ct/mri scan of the abdomen, ct of the chest and brain and a negative bone scan.
Beschreibung

ID.1

Datentyp

boolean

Alias
UMLS CUI [1,1]
C2239176
UMLS CUI [1,2]
C0445092
patients undergoing local therapy (resection, ablation or chemoembolization) and those listed for liver transplantation will not be excluded from participating in the study.
Beschreibung

ID.2

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1517925
UMLS CUI [1,2]
C3697559
patients with multiple space occupying lesions within the liver (but no evidence of extra-hepatic metastases) will continue to be eligible (the distinction between regenerative nodules and multi-focal hcc versus intra-hepatic metastases can not be made with certainty by presently available techniques).
Beschreibung

ID.3

Datentyp

boolean

Alias
UMLS CUI [1]
C0577053
karnofsky performance status (kps) ≥ 60 %.
Beschreibung

ID.4

Datentyp

boolean

Alias
UMLS CUI [1]
C0206065
age 18 years or greater.
Beschreibung

ID.5

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
life expectancy of at least 12 weeks.
Beschreibung

ID.6

Datentyp

boolean

Alias
UMLS CUI [1]
C0023671
concomitant medications
Beschreibung

ID.7

Datentyp

boolean

Alias
UMLS CUI [1]
C2347852
patients should be on stable doses of other medications (no change in dose for two weeks prior to study initiation) when entered into the study.
Beschreibung

ID.8

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1547311
UMLS CUI [1,2]
C0013227
patient consent must be obtained from all patients prior to entry into the trial.
Beschreibung

ID.9

Datentyp

boolean

Alias
UMLS CUI [1]
C0021430
patients must be accessible for treatment and follow-up i.e. residing within reasonable geographical limits of the study site.
Beschreibung

ID.10

Datentyp

boolean

Alias
UMLS CUI [1]
C2346719
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
any investigational agent within a minimum of 6 weeks prior to study treatment.
Beschreibung

ID.11

Datentyp

boolean

pregnant or lactating women; women or men of childbearing potential unless using effective contraception. patients capable of reproduction must agree to use appropriate methods of contraception during the study and for six months afterwards. female patients of childbearing potential must have a negative urine pregnancy test within 14 days of study enrollment.
Beschreibung

ID.12

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0032961
UMLS CUI [1,2]
C0006147
UMLS CUI [1,3]
C0009862
patients whose partners are pregnant.
Beschreibung

ID.13

Datentyp

boolean

Alias
UMLS CUI [1]
C0032961
other serious illness or medical conditions which would not permit the patient to be managed according to the protocol including:
Beschreibung

ID.14

Datentyp

boolean

Alias
UMLS CUI [1]
C0012634
history of a psychiatric disorder which would impair the ability to obtain consent or follow-up tumor imaging.
Beschreibung

ID.15

Datentyp

boolean

Alias
UMLS CUI [1]
C0004936
active uncontrolled infection.
Beschreibung

ID.16

Datentyp

boolean

Alias
UMLS CUI [1]
C3714514
any known defect in gaba metabolism or hypersensitivity to baclofen.
Beschreibung

ID.17

Datentyp

boolean

Alias
UMLS CUI [1,1]
C1156893
UMLS CUI [1,2]
C0571150
patients with previous organ allograft or taking immunomodulatory drugs.
Beschreibung

ID.18

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0021081
UMLS CUI [1,2]
C0029216
renal failure not being managed by dialysis.
Beschreibung

ID.19

Datentyp

boolean

Alias
UMLS CUI [1]
C0035078
Zum Seitenanfang zurückkehren

Ähnliche Modelle

Eligibility Hepatocellular Carcinoma NCT00493428

1 Formulare
Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
a diagnosis of hcc and no evidence of extra-hepatic metastases on ct/mri scan of the abdomen, ct of the chest and brain and a negative bone scan.
boolean
C2239176 (UMLS CUI [1,1])
C0445092 (UMLS CUI [1,2])
ID.2
Item
patients undergoing local therapy (resection, ablation or chemoembolization) and those listed for liver transplantation will not be excluded from participating in the study.
boolean
C1517925 (UMLS CUI [1,1])
C3697559 (UMLS CUI [1,2])
ID.3
Item
patients with multiple space occupying lesions within the liver (but no evidence of extra-hepatic metastases) will continue to be eligible (the distinction between regenerative nodules and multi-focal hcc versus intra-hepatic metastases can not be made with certainty by presently available techniques).
boolean
C0577053 (UMLS CUI [1])
ID.4
Item
karnofsky performance status (kps) ≥ 60 %.
boolean
C0206065 (UMLS CUI [1])
ID.5
Item
age 18 years or greater.
boolean
C0001779 (UMLS CUI [1])
ID.6
Item
life expectancy of at least 12 weeks.
boolean
C0023671 (UMLS CUI [1])
ID.7
Item
concomitant medications
boolean
C2347852 (UMLS CUI [1])
ID.8
Item
patients should be on stable doses of other medications (no change in dose for two weeks prior to study initiation) when entered into the study.
boolean
C1547311 (UMLS CUI [1,1])
C0013227 (UMLS CUI [1,2])
ID.9
Item
patient consent must be obtained from all patients prior to entry into the trial.
boolean
C0021430 (UMLS CUI [1])
ID.10
Item
patients must be accessible for treatment and follow-up i.e. residing within reasonable geographical limits of the study site.
boolean
C2346719 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.11
Item
any investigational agent within a minimum of 6 weeks prior to study treatment.
boolean
ID.12
Item
pregnant or lactating women; women or men of childbearing potential unless using effective contraception. patients capable of reproduction must agree to use appropriate methods of contraception during the study and for six months afterwards. female patients of childbearing potential must have a negative urine pregnancy test within 14 days of study enrollment.
boolean
C0032961 (UMLS CUI [1,1])
C0006147 (UMLS CUI [1,2])
C0009862 (UMLS CUI [1,3])
ID.13
Item
patients whose partners are pregnant.
boolean
C0032961 (UMLS CUI [1])
ID.14
Item
other serious illness or medical conditions which would not permit the patient to be managed according to the protocol including:
boolean
C0012634 (UMLS CUI [1])
ID.15
Item
history of a psychiatric disorder which would impair the ability to obtain consent or follow-up tumor imaging.
boolean
C0004936 (UMLS CUI [1])
ID.16
Item
active uncontrolled infection.
boolean
C3714514 (UMLS CUI [1])
ID.17
Item
any known defect in gaba metabolism or hypersensitivity to baclofen.
boolean
C1156893 (UMLS CUI [1,1])
C0571150 (UMLS CUI [1,2])
ID.18
Item
patients with previous organ allograft or taking immunomodulatory drugs.
boolean
C0021081 (UMLS CUI [1,1])
C0029216 (UMLS CUI [1,2])
ID.19
Item
renal failure not being managed by dialysis.
boolean
C0035078 (UMLS CUI [1])
Zum Seitenanfang zurückkehren 

Kontakt

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Hilfe

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video